Skip to main content
. Author manuscript; available in PMC: 2022 Nov 15.
Published in final edited form as: Clin Cancer Res. 2022 May 13;28(10):2094–2109. doi: 10.1158/1078-0432.CCR-21-3570

Figure 6: HNCAF-0 and HNCAF-3 are also predictive of favorable responses to pembrolizumab.

Figure 6:

A) Protein Activity Profile Enrichment plots of single-cell protein population markers for each HNCAF cluster (Supplemental Table 1) in bulkRNA-Seq signature of pembrolizumab immunotherapy responders (R, n=5) vs non-responders (NR, n=15), profiled pre-treatment (23). B) Area Under the Receiver Operating Characteristic (AUROC) plots corresponding to pre-treatment predictive power of patient-by-patient protein activity profile enrichment for each HNCAF population show in A. 95% confidence intervals are included.